A4C Shares Insight on ADHD Medication Supply Challenges
Angels for Change was recently included in an article by Understood.org discussing the DEA’s recent changes to stimulant production limits and their impact on ADHD medication availability.
The piece explores how quota adjustments, supply-chain factors, and increasing demand continue to affect access to essential ADHD treatments. Angels for Change shared perspective on the broader issue of drug shortages and the importance of building a more resilient supply chain to ensure patients have consistent access to the medicines they need.
As A4C Founder Laura Bray shared, “Right now, the only people really feeling the burden of this brokenness are patients. All this failure and the burden of solving it has rested on the people who have the least amount of power to solve it.”
We appreciate the opportunity to contribute to this important conversation on improving medication availability and reliability for patients nationwide.
🔗 Read the full article here: DEA increases ADHD stimulant limits: What this means for the shortage